Sphingolipids are important in many brain functions but their role in Alzheimer’s disease (AD) is not completely defined. A major limit is availability of fresh brain tissue with defined AD pathology.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
March 3, 2015 11:55 AM
Beta amyloid was detected in younger brains 20 yr of age.
Brain Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease Alaina Baker-Nigh , Shahrooz Vahedi , Elena Goetz Davis , Sandra Weintraub , Eileen H. Bigio , William L. Klein , Changiz GeulaDOI: http://dx.doi.org/10.1093/brain/awv024 First published online: 2 March 2015
Krishan Maggon 's curator insight,
January 11, 2015 4:37 AM
Neurobiology of Disease Volume 73, January 2015, Pages 137–149 Review Eph receptors: New players in Alzheimer's disease pathogenesisMoustapha Cissé, , Frédéric Checler, doi:10.1016/j.nbd.2014.08.028
Krishan Maggon 's curator insight,
November 16, 2014 3:21 AM
Amyloid Beta Precursor Protein: Proper Credit for the Basic Biochemical Properties of the Most Studied Protein in the 21st Century*Franco R , Navarro G, Martínez-Pinilla E and Moreno E JOURNAL OF NEUROLOGY AND NEUROLOGICAL DISORDERS
Copyright: © 2014 Franco R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
Krishan Maggon 's curator insight,
March 18, 2015 4:11 AM
Citation: Aubry S, Shin W, Crary JF, Lefort R, Qureshi YH, et al. (2015) Assembly and Interrogation of Alzheimer’s Disease Genetic Networks Reveal Novel Regulators of Progression. PLoS ONE 10(3): e0120352. doi:10.1371/journal.pone.0120352
Krishan Maggon 's curator insight,
March 2, 2015 2:10 AM
NATURE IMMUNOLOGY | REVIEW Innate immunity in Alzheimer's diseaseMichael T Heneka,Douglas T Golenbock& Eicke LatzAffiliationsCorresponding authorNature Immunology 16, 229–236 (2015) doi:10.1038/ni.3102Received 03 December 2014 Accepted 13 January 2015 Published online 17 February 2015
Krishan Maggon 's curator insight,
January 11, 2015 4:29 AM
Pharmacological Reports
Volume 67, Issue 2, April 2015, Pages 195–203 Review article A review on Alzheimer's disease pathophysiology and its management: an updateAnil Kumar, , , Arti Singh, Ekavali doi:10.1016/j.pharep.2014.09.004
Krishan Maggon 's curator insight,
November 2, 2014 1:56 AM
Review Immunotherapy for Alzheimer’s disease: hoops and hurdlesCynthia A Lemere Correspondence: Cynthia A Lemere clemere@partners.org Author Affiliations Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, NRB 636F, 77 Avenue Louis Pasteur, Boston 02115, MA, USA Molecular Neurodegeneration 2013, 8:36 doi:10.1186/1750-1326-8-36 The electronic version of this article is the complete one and can be found online at:http://www.molecularneurodegeneration.com/content/8/1/36 Received:3 July 2013Accepted:23 September 2013Published:22 October 2013 © 2013 Lemere; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Citation: Fonteh AN, Ormseth C, Chiang J, Cipolla M, Arakaki X, et al. (2015) Sphingolipid Metabolism Correlates with Cerebrospinal Fluid Beta Amyloid Levels in Alzheimer’s Disease. PLoS ONE 10(5): e0125597. doi:10.1371/journal.pone.0125597